Patients who take a close look at medical science in search of treatments are often appalled by what they discover. On the one hand, there's academic research, a self-contained and self-absorbed universe of its own where data may be internally consistent (on a good day) and robustly reproducible, yet often has little relevance to real-world clinical conditions.

It’s easy to muster a cynical response to Tuesday’s announcement that the world’s largest health products company, J&J, is replacing their current CEO William Weldon (athletic white male and former sales rep who rose through the commercial organization) with Alex Gorsky (athletic ...

Our new research shows that, compared to illegal counterfeit pharmaceuticals, substandard legal medicines can pose an equally dangerous threat.

Recent court decisions in India endanger drug investment.

India has enormous potential for drug development if its legal system will respect intellectual property.

India has a choice: itcan either follow the route it has taken in software engineering or it can travel the opposite route with idiosyncratic rules that limit growth and innovation.

The core of medicine, and medical research, is and must be the patient, and the success of future drug development will depend upon our ability to keep patients in the front of our minds and at the center of our efforts.

India is at a crossroads. It can follow the route it has taken in software engineering, or it can travel the opposite route with idiosyncratic rules that limit growth and innovation.